Welcome to our dedicated page for Vaxcyte news (Ticker: PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte stock.
Vaxcyte, Inc. reports clinical-stage vaccine developments focused on bacterial diseases, led by pneumococcal conjugate vaccine candidates in its PCV franchise. Recurring updates cover VAX-31 clinical studies in adult and infant populations, earlier PCV candidates including VAX-24 and VAX-XL, and pipeline programs such as VAX-A1 for Group A Strep and VAX-GI for Shigella.
Company news also addresses the XpressCF cell-free protein synthesis platform licensed from Sutro Biopharma, manufacturing and commercial-readiness activities, equity financings, quarterly financial results, and healthcare conference participation. These releases tie Vaxcyte’s vaccine engineering platform to clinical progress, supply-chain development, and capital resources supporting its pipeline.
Vaxcyte, Inc. (Nasdaq: PCVX) reported its Q3 2021 financials and business updates, announcing the completion of the GMP drug product manufacturing and GLP toxicology study for its VAX-24 vaccine. The company anticipates submitting the VAX-24 IND application to the FDA in Q1 2022. Q3 net loss was $26.6 million, compared to $21.0 million in Q3 2020. R&D expenses rose to $20.4 million from $16.4 million, attributed to personnel and project-related costs. Cash reserves as of September 30, 2021, were $318.3 million, down from $386.2 million at year-end 2020.
Vaxcyte, Inc. (Nasdaq: PCVX) announced the appointment of Carlos Paya as Board Chair and Michael Kamarck to its board of directors. Both leaders bring extensive experience in biopharmaceuticals and vaccine development. CEO Grant Pickering emphasized their expertise will help advance Vaxcyte’s mission to create next-generation vaccines, including the VAX-24 pneumococcal vaccine. The company aims to improve global health by developing superior vaccines targeting infectious diseases.
Vaxcyte, Inc. (Nasdaq: PCVX) announced participation in a fireside chat at the Guggenheim 2nd Annual Vaccine and Infectious Disease Conference on October 5, 2021, at 11:30 am ET. A live webcast will be available through the Company’s website, with a replay accessible for 30 days post-conference. Vaxcyte focuses on developing novel vaccines to combat infectious diseases, featuring advanced technologies like the XpressCF™ platform. Their lead candidate, VAX-24, targets invasive pneumococcal disease.
On September 21, 2021, Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in the 2021 Cantor Virtual Global Healthcare Conference. This event will take place on September 28, 2021, at 8:40 AM ET. A live webcast will be available on the company's website, with a replay accessible for 30 days post-conference. Vaxcyte is focused on developing advanced vaccines against common infectious diseases, with its lead candidate, VAX-24, targeting invasive pneumococcal disease.
Vaxcyte (Nasdaq: PCVX) announced the appointment of Annie Drapeau and Teri Loxam to its board of directors, following the departure of Patrick Heron and Rob Hopfner. CEO Grant Pickering expressed confidence in the new appointees' extensive experience in biopharmaceuticals and technology, which will support Vaxcyte's lead program, VAX-24, a pneumococcal conjugate vaccine. Drapeau previously led HR at Moderna, while Loxam is currently CFO at SQZ Biotechnologies, enhancing Vaxcyte's leadership at a pivotal time for its vaccine pipeline.
Vaxcyte, Inc. (Nasdaq: PCVX) announced its Q2 2021 financial results, reporting a net loss of $23.7 million, up from $20.3 million in Q2 2020. As of June 30, 2021, cash and investments stood at $341.0 million, down from $386.2 million at the end of 2020. The company is advancing its lead pneumococcal vaccine candidate, VAX-24, and is on track for an IND application submission between January and June 2022. Vaxcyte also secured an additional $3.2 million from CARB-X for VAX-A1, a vaccine targeting Strep infections. Operational expenses saw R&D at $17.7 million and G&A at $6.1 million.
Vaxcyte, Inc. (Nasdaq: PCVX) announced an additional $3.2 million grant from CARB-X, bringing total potential funding to $29.7 million for the development of its vaccine candidate, VAX-A1. This funding aims to enable the Investigational New Drug (IND) application for VAX-A1, a vaccine targeting Group A Streptococcus, which causes 700 million cases of illness annually. The vaccine is critical in addressing antibiotic resistance and reducing morbidity and mortality related to this widespread infection.
Vaxcyte, Inc. (Nasdaq: PCVX), a company focused on next-generation vaccines, will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 4:00 PM ET. The event aims to showcase its innovative vaccine solutions designed to combat severe infectious diseases.
The presentation will be accessible via the company’s website, with a replay available for 30 days. Vaxcyte is known for its advanced cell-free protein synthesis platform and its lead candidate, VAX-24, targeting invasive pneumococcal disease.
Vaxcyte, Inc. (Nasdaq: PCVX) reported Q1 2021 financial results and updates on its vaccine pipeline. As of March 31, 2021, it had $370.9 million in cash. R&D expenses decreased to $17.3 million, while G&A expenses rose to $5.9 million, resulting in a net loss of $21.2 million. The company is progressing with its 24-valent pneumococcal vaccine, VAX-24, aiming to submit an IND application to the FDA by mid-2022. Vaxcyte also appointed Janet Graesser as Vice President of Corporate Communications, enhancing its strategic communications.
Vaxcyte announced the publication of preclinical data for its investigational VAX-24 vaccine in Vaccine, showing that all 24-valent serotypes in VAX-24 elicited robust immune responses compared to existing vaccines. This 24-valent pneumococcal conjugate vaccine targets strains not covered by the current 13-valent vaccine, addressing a significant unmet medical need in preventing invasive pneumococcal disease. Vaxcyte plans to submit an Investigational New Drug application to the FDA for VAX-24, advancing towards clinical trials.